Institutional members access full text with Ovid®

Share this article on:

Immunogenicity and Safety of Measles-Mumps-Rubella, Varicella and Haemophilus influenzae Type b Vaccines Administered Concurrently With a Fourth Dose of Heptavalent Pneumococcal Conjugate Vaccine Compared With the Vaccines Administered Without Heptavalent Pneumococcal Conjugate Vaccine

Black, Steven B. MD*; Cimino, Carolyn O. BS; Hansen, John BA*; Lewis, Edwin MPH*; Ray, Paula MPH*; Corsaro, Bartholomew PhD; Graepel, Jay PhD; Laufer, Dagna MD

The Pediatric Infectious Disease Journal: April 2006 - Volume 25 - Issue 4 - p 306-311
doi: 10.1097/01.inf.0000207409.92198.6f
Original Studies

Background: Prevnar [heptavalent pneumococcal conjugate vaccine (PCV7)] is licensed in the United States for routine administration in infants and may be coadministered with other infant vaccines. Safety and immunogenicity data on the coadministration of the fourth dose of PCV7 with measles-mumps-rubella (MMR), varicella and Haemophilus influenzae type b (Hib) vaccines are limited.

Methods: Children 12–15 months of age received either MMR with PCV7 (group 1) or MMR without PCV7 (group 2). All subjects received Hib and varicella vaccines. Group 2 received PCV7 6–9 weeks after MMR vaccination. Sera for analysis of all non-PCV7 antibodies were collected just before administration of MMR vaccine and 6 weeks later. Optimal antigen responses were assessed with the use of predetermined antibody titers. The primary end point was >90% response rate (all antigens). Noninferiority was defined as <10% difference between groups. Local and systemic reactions and postvaccination adverse events were monitored and compared between groups.

Results: A total of 694 subjects (347 per group) were enrolled. After immunization with MMR plus PCV7 concurrently, or MMR followed 6 weeks later by PCV7, the percentages of subjects seroconverting were significantly greater than 90% for all antigens. The difference between the 2 groups was significantly less than 10%.

Conclusion: The immune response to MMR, Hib and varicella vaccines, when administered concurrently with a 4th (booster) dose of PCV7, was noninferior to that of these vaccines when given without PCV7. These results support concomitant administration of PCV7 with MMR, varicella and Hib as part of the recommended immunization schedule for children 12–15 months of age.

From the *Kaiser Permanente Vaccine Study Center, Oakland, CA; †Global Medical Affairs and ‡Vaccines, Wyeth Pharmaceuticals, Collegeville, PA

Accepted for publication November 11, 2005.

Supported by Wyeth Pharmaceuticals, Collegeville, PA.

Presented in part at the Pediatric Academic Societies Annual Meeting, May 1-4, 2004, San Francisco, CA.

Dr Corsaro, Dr Laufer and Ms Cimino own stock in Wyeth Pharmaceuticals, Inc.

Address for reprints: Steven Black, MD, Kaiser Permanente Vaccine Study Center, 1 Kaiser Plaza-16B, Oakland, CA 94612. Fax 510-267-7524; E-mail

© 2006 Lippincott Williams & Wilkins, Inc.